Age, years, median and IQR |
55 (46-65) |
Female, n (%) |
63 (87.5) |
dcSSc, n (%) |
33 (45.8) |
Disease duration, years, median and IQR |
11
(6-20) |
mRSS, median and IQR |
13 (7-18) |
SSc-specific autoantibodies: |
|
Anti-topoisomerase I, n (%) |
33 (45.8) |
Anti-centromere, n (%) |
24 (33.3) |
Anti-RNA polymerase III, n (%) |
4 (5.6) |
None, n (%) |
11 (15.3) |
DAI, median and IQR |
1.5 (0.8-2.9) |
DSS. median and IQR |
5 (4-6) |
Telangiectasias, n (%) |
38 (52.8%) |
ESR, mm/h, median and IQR |
19 (12-34) |
CRP, mcg/L, median and IQR |
1600 (800-3500) |
C3, mg/L, median and IQR |
1045 (925-1180) |
Nailfold capillaroscopic pattern: |
|
Early, n (%) |
13 (18.1) |
Active, n (%) |
23 (31.9) |
Late, n (%) |
36 (50) |
sCr, mg/dL, median and IQR |
0.8 (0.6-0.9) |
eGFR, mL/min, median and IQR |
93 (80-108) |
Arterial hypertension, n (%) |
22 (30.6%) |